Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05257408 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Relacorilant in Combination With Nab-Paclitaxel in Advanced, Platinum-Resistant, High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian-Tube Cancer

StatusActive, Not Recruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary endpoint reworded 2 of 2 changed
See other at-risk trials from Corcept Therapeutics

Record History

The 50 most recent of 60 record versions are listed below. See every version on ClinicalTrials.gov ↗

  1. Primary endpoint(s) modified Results posted: Sep 25, 2026 · Completion pushed from Mar 2026 to Dec 2026 · Interventions modified · 3 more Show 6 more changesShow less
    • Results posted: Sep 25, 2026
    • Completion pushed from Mar 2026 to Dec 2026
    • Interventions modified
    • Study sites: 117 to 116
    • Eligibility criteria expanded, about 33 words
    • Secondary endpoints revised (9)
  2. Primary endpoints revised (2) Primary completion date: Mar 24, 2025 to Mar 31, 2025 · Completion date: Mar 2026 to Dec 2026 · Interventions: Nab-paclitaxel 100 mg/m^2 (Drug), Nab-paclitaxel 80 mg/m^2 (Drug), Relacorilant 150 mg once daily (QD) (Drug) to Nab-paclitaxel 100 mg/m^2 (Drug), Nab-paclitaxel 80 mg/m^2 (Drug), Relacorilant 150 mg (Drug) · 1 morev59 Show 4 more changesShow less
    • Primary completion date: Mar 24, 2025 to Mar 31, 2025
    • Completion date: Mar 2026 to Dec 2026
    • Interventions: Nab-paclitaxel 100 mg/m^2 (Drug), Nab-paclitaxel 80 mg/m^2 (Drug), Relacorilant 150 mg once daily (QD) (Drug) to Nab-paclitaxel 100 mg/m^2 (Drug), Nab-paclitaxel 80 mg/m^2 (Drug), Relacorilant 150 mg (Drug)
    • Secondary endpoints: 7 to 9

    See this version in full on ClinicalTrials.gov ↗

  3. Primary completion date changed from estimate of Mar 2025 to Mar 24, 2025v58
  4. Primary completion date: Mar 2026 to Mar 2025v57
  5. Primary completion date: Dec 2024 to Mar 2026 Enrollment target: estimated 360 to confirmed 381 · Completion date: Dec 2025 to Mar 2026v56 Show 2 more changesShow less
    • Enrollment target: estimated 360 to confirmed 381
    • Completion date: Dec 2025 to Mar 2026
Show 45 earlier versionsHide 45 earlier versions
  1. Primary completion date: Jun 2024 to Dec 2024 Completion date: Jun 2025 to Dec 2025v55 Show 1 more changeShow less
    • Completion date: Jun 2025 to Dec 2025
  2. Trial status: Recruiting to Active, Not Recruiting Site details revised at 117 of 117 sitesv54 Show 1 more changeShow less
    • Site details revised at 117 of 117 sites
  3. Study sites: 116 to 117v53
  4. Re-verified, no change to tracked fieldsv52
  5. Study sites: 115 to 116v51
  6. Study sites: 114 to 115v50
  7. Study sites: 113 to 114v49
  8. Study sites: 111 to 113v48
  9. Study sites: 109 to 111v47
  10. Study sites: 108 to 109v46
  11. Study sites: 107 to 108v45
  12. Study sites: 106 to 107v44
  13. Study sites: 103 to 106v43
  14. Re-verified, no change to tracked fieldsv42
  15. Study sites: 100 to 103v41
  16. Study sites: 98 to 100v40
  17. Study sites: 97 to 98v39
  18. Study sites: 95 to 97v38
  19. Re-verified, no change to tracked fieldsv37
  20. Study sites: 93 to 95v36
  21. Study sites: 92 to 93v35
  22. Study sites: 91 to 92v34
  23. Study sites: 90 to 91v33
  24. Study sites: 89 to 90v32
  25. Study sites: 87 to 89v31
  26. Study sites: 86 to 87v30
  27. Study sites: 85 to 86v29
  28. Re-verified, no change to tracked fieldsv28
  29. Study sites: 82 to 85v27
  30. Study sites: 55 to 82v26
  31. Study sites: 53 to 55v25
  32. Study sites: 49 to 53v24
  33. Study sites: 48 to 49v23
  34. Study sites: 42 to 48v22
  35. Study sites: 38 to 42v21
  36. Study sites: 37 to 38v20
  37. Study sites: 36 to 37v19
  38. Re-verified, no change to tracked fieldsv18
  39. Study sites: 35 to 36v17
  40. Study sites: 33 to 35v16
  41. Study sites: 31 to 33v15
  42. Study sites: 29 to 31v14
  43. Study sites: 26 to 29v13
  44. Study sites: 25 to 26v12
  45. Re-verified, no change to tracked fieldsv11
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The primary objectives of this study are to evaluate progression-free survival (PFS) by blinded independent central review (BICR) and overall survival (OS) (evaluated independently, as dual primary endpoints) in patients treated with intermittent regimen of relacorilant in combination with nab-paclitaxel compared with patients treated with nab-paclitaxel monotherapy.
Trial Details
NCT Number NCT05257408
Lead Sponsor Corcept Therapeutics
Collaborators: Gynecologic Oncology Group
Conditions Ovarian Neoplasm, Fallopian Tube Neoplasms, Peritoneal Neoplasms
Enrollment 381 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov